Spectral Medical Inc
Open
$1.35
Prev. Close
$1.34
High
$1.35
Low
$1.35
Market Snapshot
$236.65M
-0.17
$2.44M
29
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. The company has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. The company is continuing its legacy business of manufacturing and selling certain proprietary reagents. The company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
emptyResult
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. The company has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. The company is continuing its legacy business of manufacturing and selling certain proprietary reagents. The company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Recently from Cashu
Spectral Medical Inc. Files Shelf Prospectus to Enhance Financial Flexibility and Support Innovation
Spectral Medical Inc. Enhances Financial Flexibility with New Shelf Prospectus On July 4, 2025, Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company specializing in treatments for sepsis…
Spectral Medical Inc. Advances Leadership and Focus on Septic Shock Treatment Innovations
Spectral Medical Inc. Strengthens Leadership and Focuses on Septic Shock Therapeutics Spectral Medical Inc. successfully concludes its Annual Meeting of shareholders on June 5, 2025, where all resolut…
Spectral Medical Inc. Advances Sepsis Treatment with Toraymyxin™ Amid FDA Approval Efforts
Spectral Medical Advances in Sepsis Treatment with Toraymyxin™ Spectral Medical Inc. is at the forefront of developing innovative treatments for sepsis and septic shock, a critical health concern affe…
Spectral Medical Inc. Enhances Stakeholder Engagement with Tegris Trial Updates and Strategic Vision
Spectral Medical Inc. Enhances Stakeholder Engagement with Tegris Trial Update Spectral Medical Inc. demonstrates its commitment to transparency and stakeholder engagement during a recent special call…